母婴阻断中抗乙型肝炎病毒药物核苷(酸)类似物的治疗进展  

Progress in treatment of anti-hepatitis B virus drug nucleoside analogues in preventing mother-to-child transmission

作　　者：郑洲松 黄燕[2] 黄泽炳[2] ZHENG Zhou-song;HUANG Yan;HUANG Ze-bing(Zhuzhou Hospital Affiliated to Xiangya School of Medicine,Central South University,Zhuzhou Hunan 412007,China;Dept of Infectious Diseases,Xiangya Hospital,Central South University,Key Laboratory of Viral Hepatitis of Hunan Province,National Clinical Research Center for Geriatrics,Changsha 410008,China)

机构地区：[1]中南大学湘雅医学院附属株洲医院,湖南株洲412007 [2]中南大学湘雅医院感染病科,病毒性肝炎湖南省重点实验室,国家老年疾病临床医学研究中心,湖南长沙410008

出　　处：《中国药理学通报》2023年第12期2221-2224,共4页Chinese Pharmacological Bulletin

基　　金：国家科技重大专项(No 2018ZX10723203-004-003)。

摘　　要：母婴传播是乙型肝炎病毒(hepatitis B virus,HBV)传播的主要途径之一,也是HBV感染后慢性化的主要原因,因此,阻断HBV母婴传播对于降低慢性乙型肝炎发病率尤为重要。目前,用于HBV母婴阻断的核苷(酸)类似物(Nas)有拉米夫定、替比夫定、富马酸替诺福韦二吡呋酯,富马酸丙酚替诺福韦亦开始用于妊娠期慢性乙型肝炎患者。该文总结上述药物在HBV母婴阻断中的疗效、安全性以及抗病毒治疗指征和停药时间,为母婴阻断Nas的选择及合理应用提供参考。Mother-to-child transmission of hepatitis B virus(HBV)is one of the main ways of transmission and the main cause of chronic hepatitis B after infection.Therefore,preventing mother-to-child transmission of HBV is particularly important in reducing the incidence of chronic hepatitis B.Currently,nucleoside(acid)analoids(Nas)used for mother-to-child blocking of HBV include lamivudine(LAM),tibivudine(LdT)and tenofovir fumarate(TDF).Propofol tenofovir fumarate(TAF)has also been used in pregnant chronic hepatitis B patients.This paper summarizes the efficacy,safety and antiviral treatment indications and termination time of the above-mentioned drugs in mother-to-child preventing to provide suggestions for the selection and rational application of mother-to-child preventing Nas.

关 键 词：慢性乙型肝炎 母婴阻断 核苷(酸)类似物 疗效 安全性 治疗进展 

分 类 号：R342.5[医药卫生—基础医学] R373.21R725.126.2R977R978.7